ERBB2 and breast cancer: Treatment options of Her2+ breast cancer patients has improved with the advent of targeted antibodies (Pertuzumab and Trastuzumab) and kinase inhibitors (Lapatinib, Afatinib, Neratinib), but inherent and acquired resistance to these therapies remains a major clinical problem for patients with this breast cancer subtype [9, 10].